20 ('Have you ever had delirium tremens or seizures, severe shaking, heard voices or seen things that were not there after heavy drinking?'). None of these analyses yielded a significant association with the NR2B genotype. We performed additional subdivisions of our sample with respect to sex and psychiatric comorbidity, including affective disorders, anxiety disorders and substance abuse other than alcohol dependence. No significant association with the NR2B genotype was observed (Cochran-Armitage test, data not shown).
Clozapine-induced reduction of glutamate transport in the frontal cortex is not mediated by GLAST and EAAC1 Molecular Psychiatry (2003) 8, 12-13. doi:10.1038/ sj.mp.4001193 SIR -Glutamate (Glu), the main excitatory neurotransmitter in the cerebral cortex, has been implicated in several neuropsychiatric disorders, including schizophrenia. 1 The effects of Glu are determined, among others, by the action of high-affinity Glu transporters (GluTs). 2 To date, five GluTs have been characterized: GLT-1, GLAST, EAAC1, EAAT4, and EAAT5. 2, 3 Clozapine, a highly effective antipsychotic, 4 increases the extracellular levels of Glu in the rat frontal cortex. 5, 6 Recently, we showed that clozapine reduces cortical expression of GLT-1 and decreases total Glu uptake by 60% in the rat frontal cortex, 6 suggesting that the clozapine-induced increase in Glu levels depends on GLT-1 down-regulation. In the neocortex, EAAT4 and EAAT5 expression is poor or absent 3 and therefore their contribution to total cortical Glu uptake is extremely small, whereas GLAST and EAAC1 are robustly expressed 7, 8 and mediate a sizeable fraction of total Glu uptake. 9 Whether the expression of GLAST and EAAC1 is altered by clozapine is unknown.
Thus, we used immunocytochemical and Western blotting methods to investigate whether clozapine affects GLAST and EAAC1 expression in the frontal cortex of adult rats. Animal care and handling, treatment regimen (oral administration), doses (0.5 mg/ml in drinking water), and length of treatment (9 weeks) were as described in a recent report; 6 based on previous studies in rats (reported by Melone et al 6 ), estimated clozapine plasma levels were 20-60 ng/ml. For immunocytochemistry (six treated and six controls), 30-mm-thick sections were processed as described 8 using affinity-purified polyclonal (GLT-1: 0.010 mg/ml; GLAST: 0.08 mg/ml; C-and N-terminal respectively), previously characterized 10 and kindly provided by Dr JD Rothstein, or monoclonal antibodies (EAAC1: 1 : 80; Chemicon, MAB1587). For immunoblotting, rats (four treated and four controls) were perfused as described 6 and cortical regions rostral to the bregma were homogenized in 6 vol of ice-cold buffer (4 mM Tris-HCl, pH 7.4; 0.32 M sucrose; 1 mM EDTA; 0.23 mM dithiothreitol; 1 mM leupeptin and pepstatin A). Homogenate processing, protein concentration determination, and blotting onto nitrocellulose filters probed with GLT-1 (0.02 mg/ml), GLAST (0.10 mg ml), or EAAC1 (1 : 150) antibodies were performed as described. 6 Labelled bands visualization and densitometric analysis were performed using BioRad Chemidoc and Quantity One software. Results were normalized to GLT-1 levels in controls prepared in parallel and loaded onto the same gel. Significance was evaluated by the MannWhitney U-test.
In the frontal cortex of controls, GLT-1, GLAST, and EAAC1 immunoreactivities (ir) (Figure 1a , c, and e) were as described previously. 3, 7, 8, 10 In treated rats, GLT-1-ir was reduced (Figure 1b) , whereas GLAST and EAAC1 ir were as in controls (Figure 1d and f ) . Immunoblotting of samples from treated and control rats showed that the antiGLT-1, GLAST, and EAAC1 antibodies recognized proteins of 70, 65, and 69 kDa (Figure 1g) , consistent with the molecular weight of the three proteins. 3 In the cortex of treated rats, densitometric analysis showed significantly reduced GLT-1 (42. (Figure 1h) .
Here we showed that clozapine administration (25-35 mg/kg/day; 9 weeks) strongly reduces GLT-1, but not GLAST or EAAC1, expression. Since both experimental series were from the same material and processed in parallel in identical conditions, it may be concluded that clozapine does not affect GLAST and EAAC1 expression (at least to an extent detectable by current techniques). Thus, the robust decrease of Glu uptake and the consequent increase in Glu levels demonstrated in the frontal cortex of rats receiving the same treatment as used here 6 can be attributed to a specific effect of clozapine on GLT-1 expression and function. Our results also suggest that at glutamatergic synapses where clozapine reduces GLT-1 expression, GLAST and EAAC1 do not mediate a compensatory increase of Glu uptake.
Mounting evidence indicates that some symptoms of schizophrenia are related to a reduced efficacy of glutamatergic transmission. 1 Our previous demonstration that clozapine strongly reduces GLT-1 expression and function and total Glu transport 6 and the present evidence for its lack of effect on GLAST and EAAC1 expression suggest that clozapine exerts at least part of its therapeutic effects by a selective GLT-1-mediated reduction of Glu uptake that potentiates glutamatergic transmission. 
